Open-Label Trial of MABp1, a True Human Monoclonal Antibody Targeting Interleukin 1α, for the Treatment of Psoriasis

Open-Label Trial of MABp1, a True Human Monoclonal Antibody Targeting Interleukin 1α, for the Treatment of Psoriasis MABp1is a true human monoclonal antibody specific for interleukin 1α (IL-1α), a key proinflammatory cytokine involved in sterile inflammation that is abundantly present in psoriatic skin lesions. 1 MABp1 differs from previous generations of therapeutic antibodies in that it was cloned from an Epstein-Barr virus-immortalized human B cell that was isolated from an individual with endogenous anti-IL-1α antibodies, and it has not undergone any in vitro affinity maturation. 2 Thus, there is potential for decreased antidrug antibody formation, which should lead to a profile of fewer adverse effects and less loss of effectiveness over time. 3